Femasys Inc. (FEMY) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares…
November 12, 2024
November 12, 2024
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a…
November 12, 2024
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a…
NEW YORK, November 11, 2024–(BUSINESS WIRE)–Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in…
November 08, 2024
Establishment Labs Holdings Inc (ESTA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth …
Revenue: $40.2 million for Q3 2024, a 4.5% increase from the previous year. Gross Profit: $25.7 million, representing 63.9% of revenue. Net Loss: $13.1 million…
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61….
November 07, 2024
Establishment Labs Announces $50 Million Registered Direct Offering
NEW YORK, November 07, 2024–(BUSINESS WIRE)–Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness,…
November 07, 2024
Establishment Labs Reports Third Quarter 2024 Financial Results
NEW YORK, November 07, 2024–(BUSINESS WIRE)–Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in…
November 07, 2024
Dare Bioscience (DARE) Upgraded to Buy: Here’s What You Should Know
Dare Bioscience, Inc. (DARE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is…
November 07, 2024
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here’s What You Should Know
Nuvectis Pharma, Inc. (NVCT) closed the last trading session at $8.15, gaining 34.3% over the past four weeks, but there could be plenty of upside…
November 07, 2024
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here’s What You Should Know
Nuvectis Pharma, Inc. (NVCT) closed the last trading session at $8.15, gaining 34.3% over the past four weeks, but there could be plenty of upside…
November 07, 2024
Femasys to Exhibit at the Annual AAGL 2024 Global Conference
Premier conference focused on gynecological surgery ATLANTA, Nov. 07, 2024 (GLOBE NEWSWIRE) — Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant…